IMPACT OF SMOKING HISTORY ON THE REAL-WORLD EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITORS IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER: A NATIONWIDE POPULATION-BASED STUDY

被引：0
|
作者：
Lee, J. [1 ]
Kim, Y. [2 ,3 ]
Suh, H. S. [4 ]
机构：
[1] Kyung Hee Univ, Inst Regulatory Innovat Sci, Grad Sch, Dept Regulatory Sci, Seoul, South Korea
[2] Kyung Hee Univ, Inst Regulatory Innovat Sci IRIS, Coll Pharm, Seoul, South Korea
[3] Univ Texas Austin, Coll Pharm, Hlth Outcomes Div, Austin, TX USA
[4] Kyung Hee Univ, Inst Regulatory Innovat Sci, Coll Pharm, Dept Regulatory Sci,Grad Sch, Seoul, South Korea
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The Impact of Inflammatory Serum Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
    Cipriano, E.
    Magalhaes, H.
    Estevinho, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S255 - S255
  • [42] Smoking history as an independent predictor for immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC).
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao V.
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    CANCER RESEARCH, 2021, 81 (13)
  • [43] Treatment Pattern in Small Cell Lung Cancer: A Real-world Observational Study in the Era of Immune Checkpoint Inhibitors
    Zu, K.
    Arunachalam, A.
    Macdonald, S.
    Wang, Y.
    Wells, K.
    Oliveria, S.
    Pietanza, M. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1184 - S1184
  • [44] Real-world evidence of advanced non-small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy
    Xu, Zihan
    Zhang, Huien
    Ma, Guikai
    Meng, Wenjuan
    Du, Junliang
    Wu, Xin
    Yang, Baohong
    Wang, Ningning
    Ding, Yanhong
    Zhang, Qingyun
    Li, Na
    Zhang, Xuede
    Yu, Guohua
    Liu, Shuzhen
    Li, Zhenhua
    ONCOLOGY LETTERS, 2024, 28 (03)
  • [45] Adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A single center, real-world study in China.
    Xu, Chongrui
    Tu, Hai-Yan
    Sun, Yueli
    Li, Yang-Si
    Xu, Bingfei
    Wang, Binchao
    Chen, Hua-Jun
    Wang, Zhen
    Zhou, Qing
    Yang, Jinji
    Yang, Qi
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Predictive impact of sarcopenia in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A retrospective study
    Feng, Ying
    Wang, Liyu
    Zhu, Fan
    Shi, Jianming
    Wang, Yan
    Zhang, Yingru
    Chen, Xiaofeng
    Zhang, Luyao
    HELIYON, 2024, 10 (05)
  • [47] Outcomes with chemotherapy for metastatic non-small cell lung cancer (mNSCLC) in patients previously treated with immune checkpoint inhibitors (CPI).
    Elnair, Radowan
    Chang, Guy Vin
    Powell, Steven Francis
    Sumey, Christopher Joseph
    Bleeker, Jonathan Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors
    Herzog, Brett H.
    Waqar, Saiama N.
    Devarakonda, Siddhartha
    Ward, Jeffrey P.
    Gao, Feng
    Govindan, Ramaswamy
    Morgensztern, Daniel
    LUNG CANCER, 2022, 173 : 101 - 106
  • [49] Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Xue, Chongxiang
    Dong, Huijing
    Chen, Ying
    Lu, Xingyu
    Zheng, Shuyue
    Cui, Huijuan
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (06): : 779 - 788
  • [50] Highlights on immune checkpoint inhibitors in non-small cell lung cancer
    Shen, Meng
    Ren, Xiubao
    TUMOR BIOLOGY, 2017, 39 (03)
12345